Sustained release formulations for delivery of proteins to the eye and methods of preparing same
View Patent ↗The present invention provides for injectable pharmaceutical sustained release formulations for delivery of active agents, particularly therapeutic proteins, to the eye. The formulations are biocompatible, biodegradable sustained release formulations comprising low-solubility liquid excipients and relatively small amounts (less than about 10%) of biocompatible, biodegradable polymer such as PLA or PLGA polymers. A unit dose of 5 μL to 100 μL of the formulation provides for sustained release of the agent for at least 14 days.
1. A liquid pharmaceutical formulation for injection into the eye for the sustained release of a therapeutic protein comprising:
a liquid, biodegradable, biocompatible non-polymeric excipient, wherein said excipient is benzyl benzoate; and
a biodegradable, biocompatible poly(d,l-lactide-co-glycolide) (PLGA) polymer having a lactide:glycolide ratio of 50:50, MW range 7,000-17,000, and an alkyl ester end group;
wherein the wt % ratio of non-polymeric excipient:polymer is about 90:10 to 99:1, inclusive;
wherein upon and following injection of about 5 μL to about 100 μL, inclusive of the formulation, using a 25, 27, 28, 30 gauge, or smaller needle, the formulation maintains its monolithic integrity and liquid state; and
wherein the formulation releases the therapeutic protein from the liquid formulation for a period of at least about 14 days.
2. The liquid pharmaceutical formulation of claim 1 , wherein the formulation is a unit dosage of about 5 μl to about 100 μl that can injected into the subconjunctiva, periocular space, retrobulbar in the orbit, episclera, intracornea, intrasclera, anterior chamber, anterior segment, posterior chamber, posterior segment, vitreous cavity, subretinal space, suprachorodial segment or intraretinal area of the eye.
3. The liquid pharmaceutical formulation of claim 1 , wherein the therapeutic protein is an antibody.
4. A method for administering a therapeutic protein to a subject in need thereof comprising administering to the subject's eye an effective amount of the liquid pharmaceutical formulation of claim 1 .
5. A syringeable liquid ophthalmic formulation comprising:
a pharmaceutically active protein in a therapeutically effective amount for a subject in need thereof;
an amount of benzyl benzoate; and
a biodegradable, biocompatible poly(d,l-lactide-co-glycolide) (PLGA) polymer having a lactide:glycolide ratio of 50:50, MW range 7,000-17,000, and an alkyl ester end group;
wherein the wt % ratio of benzyl benzoate:polymer ranges from 90:10 to 99:1, inclusive;
wherein said pharmaceutically active protein is solubilized or dispersed in said liquid ophthalmic formulation;
wherein a volume of about 5 μl to about 100 μl inclusive of the liquid ophthalmic formulation is syringeable through a 25, 27, 28, 30 gauge, or smaller, needle; and
wherein upon injection and thereafter, the liquid ophthalmic formulation maintains a liquid bolus state while the pharmaceutically active protein is released for at least about 14 days.
6. The syringeable liquid ophthalmic formulation of claim 5 , wherein the protein is an antibody.